Search

Your search keyword '"Weitz, Ji"' showing total 299 results

Search Constraints

Start Over You searched for: Author "Weitz, Ji" Remove constraint Author: "Weitz, Ji" Search Limiters Full Text Remove constraint Search Limiters: Full Text
299 results on '"Weitz, Ji"'

Search Results

1. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow

2. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

3. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

4. Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE

5. Edoxaban for the treatment of cancer-associated venous thromboembolism

6. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

7. Edoxaban for the treatment of cancer-associated venous thromboembolism

8. Global anticoagulant registry in the field - Venous thromboembolism (Garfield-VTE): Rationale and design

9. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients

10. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper

14. Thromboprophylaxis in surgical patients.

17. Use of a synthetic homologue of human fibrinopeptide A for production of a monoclonal antibody specific for the free peptide

18. Development of a radioimmunoassay for the fibrinogen-derived peptide B beta 1-42

22. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

23. Edoxaban versus warfarin in patients with atrial fibrillation

24. Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents

26. Histidine-Rich Glycoprotein Modulates the Toxic Effects of High-Dose Polyphosphate in Mice.

27. Global Health Burden of Venous Thromboembolism.

28. Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13.

29. Human platelets contain a pool of free zinc in dense granules.

30. Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial.

31. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.

32. Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model.

33. Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials.

34. PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice.

35. Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.

36. New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors.

37. Histidine-rich glycoprotein attenuates catheter thrombosis.

38. Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.

39. News at XI: moving beyond factor Xa inhibitors.

40. Reversal agents for current and forthcoming direct oral anticoagulants.

41. Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation.

42. Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin.

43. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.

45. On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease.

46. Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.

47. Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.

48. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.

49. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial.

Catalog

Books, media, physical & digital resources